Etrasimod for the treatment of ulcerative colitis.
Pauline WilsLaurent Peyrin-BirouletPublished in: Immunotherapy (2023)
Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new therapeutic option for ulcerative colitis patients. Etrasimod is an oral selective S1PR1, S1PR4 and S1PR5 modulator that inhibits the trafficking of lymphocytes from the lymph nodes into the blood. Recently, etrasimod has demonstrated efficacy in the phase II OASIS study and its open-label extension for the treatment of ulcerative colitis patients. This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding etrasimod, which is a promising drug in the treatment of patients with moderate to severe ulcerative colitis.
Keyphrases
- ulcerative colitis
- end stage renal disease
- open label
- phase ii
- ejection fraction
- clinical trial
- chronic kidney disease
- lymph node
- peritoneal dialysis
- oxidative stress
- prognostic factors
- systematic review
- small molecule
- emergency department
- squamous cell carcinoma
- machine learning
- early onset
- electronic health record
- high intensity
- phase iii
- artificial intelligence
- big data
- patient reported
- locally advanced
- adverse drug